Stenotrophomonas
Report Name: 2003 Stenotrophomonas maltophilia
Query Selection Criteria:
Report Start Date: 01/01/2003 (MM/DD/YYYY)
Report End Date: 12/31/2003 (MM/DD/YYYY)
Organism: Stenotrophomonas (Xanthomonas) maltophilia
Drug: Amikacin;Amoxicillin/clavulanate;Ampicillin;Ampicillin/sulbactam
;Cefazolin;Cefotaxime;Ceftazidime;Ceftriaxone;Cefuroxime;Cephalo
thin;Ciprofloxacin;Clindamycin;Erythromycin;Gentamicin;Imipenem;
Levofloxacin;Ofloxacin;Oxacillin;Penicillin;Piperacillin/tazobacta
m;Tetracycline;Ticarcillin/clavulanate;Tobramycin;Trimeth/sulfa;
Vancomycin
Breakpoint: NCCLS
Patient Type: Inpatient;Inpatient - ICU
Patient Age: greater than or equal to 18 AND less than or equal to 120
Institution: T84 University of CA at San Francisco - Parnassus
Street-ALL;T84 Mt. Zion Medical Center - Divisedero Street
Trending: None
Dataset: Institution
Chosen Country: United States
Source: TSN Database
Copyright 2004 Focus Technologies, Inc.
Organism Stenotrophomonas (Xanthomon S S I I R R
Drug Total N % N % N %
Amikacin 1 1 100.0 % 0 0.0 % 0 0.0 %
Ceftazidime 11 5 45.5 % 2 18.2 % 4 36.4 %
Ceftriaxone 1 0 0.0 % 0 0.0 % 1 100.0 %
Ciprofloxacin 0 0 N/A 0 N/A 0 N/A
Gentamicin 0 0 N/A 0 N/A 0 N/A
Imipenem 1 0 0.0 % 0 0.0 % 1 100.0 %
Piperacillin/tazobactam 10 2 20.0 % 3 30.0 % 5 50.0 %
Tetracycline 0 0 N/A 0 N/A 0 N/A
Ticarcillin/clavulanate 11 7 63.6 % 1 9.1 % 3 27.3 %
Tobramycin 0 0 N/A 0 N/A 0 N/A
Trimeth/sulfa 13 10 76.9 % 0 0.0 % 3 23.1 %
For agents with >25% of strains tested:
Plain=<60% activity